leadf
logo-loader
NASDAQ:RDHL

RedHill Biopharma

Receive alerts
Market:
NASDAQ
Market Cap:
$320.19 m
Price
7.62 USD
Change
-2.68%
52 weeks high
11.50
52 weeks low
3.28

In brief

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes three FDA-approved gastrointestinal drugs: Movantik® for opioid-induced constipation in adults, Talicia® for Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for travellers’ diarrhoea in adults. RedHill also has an extensive clinical late-stage development pipeline which includes two Phase 2/3 programs in COVID-19 (opaganib and RHB-107), RHB-204 in a Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease, RHB-104 which successfully completed a first Phase 3 study for Crohn's disease, and RHB-102 which completed a Phase 3 study for acute gastroenteritis and gastritis and a Phase 2 study for IBS-D.

Snapshot

The specialty biopharmaceutical company has three gastrointestinal products already on the market and a strong pipeline of late-stage drug candidates